title: Pharmacological studies of N-(2-mercapto-2-methylpropanoyl)-L-cysteine (SA96) (3). Effects of SA96 on experimental allergic reactions.
abstract: The effects of an antirheumatic agent, N-(2-mercapto-2-methylpropanoyl)-L-cysteine (SA96), were investigated on allergic reactions in rats and guinea pigs. The effects of SA96 were compared with those of D-penicillamine (D-Pc). SA96 given twice orally at the doses of 10 to 50 mg/kg significantly caused inhibitions of 28%, 29% and 44% against passive cutaneous anaphylaxis (PCA), reversed cutaneous anaphylaxis (RCA) and reversed passive Arthus (RPA) reactions, which are classified as Type I, Type II and Type III allergic reactions, respectively. D-Pc also showed inhibitions of 30%, 23% and 18% on Type I, Type II and Type III reactions, respectively, and inhibitions on Type II and Type III reactions were not significant. On the other hand, SA96 (10 to 50 mg/kg twice) had no influence on the Type IV allergic reaction, delayed hypersensitivity, while D-Pc (20 mg/kg twice) showed an enhancement of 27% on the Type IV reaction. In the in vitro study, SA96 inhibited the hemolytic complement activity at 10(-4) to 10(-2) M and the macrophage migration at 1 X 10(-4) to 5 X 10(-3) M in a dose-dependent manner. These in vitro activities of SA96 were more potent than those of D-Pc. These results showed that SA96 had some different immunopharmacological properties on experimental allergic reactions as compared with those of D-Pc.
authors.forename: K
authors.initials: K
authors.lastname: Nakata
authors.forename: H
authors.initials: H
authors.lastname: Suda
authors.forename: H
authors.initials: H
authors.lastname: Yamauchi
authors.forename: T
authors.initials: T
authors.lastname: Iso
mesh_terms: D000707:Anaphylaxis / Q000517:prevention & control; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001183:Arthus Reaction / Q000517:prevention & control; D002464:Cell Migration Inhibition; D003167:Complement Activation / Q000187:drug effects; D003545:Cysteine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects; D006967:Hypersensitivity / Q000517:prevention & control*; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D007073:Immunoglobulin E / Q000276:immunology; D008264:Macrophages / Q000187:drug effects; D008297:Male; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D051381:Rats; D011919:Rats, Inbred Strains
chemical_list: D000893:Anti-Inflammatory Agents; D007073:Immunoglobulin E; D003545:Cysteine; C026535:bucillamine